Previously, in a post-hoc analysis of the IMPROVE-HF trial [9] involving patients with AHF and renal dysfunction on admission, we found that sST2 was a strong predictor of CV-renal rehospitalizations only when CA125 levels exceeded 35 U/mL. Here, MUC16 is linked to Abnormal renal physiology.